Arcadia Biosciences, Inc.

As of March 30, 2022, Arcadia Biosciences, Inc. is considered a risky investment due to its low P/E and PEG ratios, negative EV to EBITDA, and underperformance compared to the S&P 500, indicating it may be overvalued.

As of March 30, 2022, Arcadia Biosciences, Inc. is considered overvalued and risky due to poor financial metrics, including a low P/E ratio of 7, a negative EV to EBITDA of -0.76, and a troubling ROCE of -91.54%, despite a recent stock return of 38.74% that underperformed the S&P 500.

As of June 18, 2025, Arcadia Biosciences, Inc. shows a bullish trend supported by strong indicators, despite some mixed signals from Dow Theory.

As of March 2022, the management team of Arcadia Biosciences, Inc. includes Chairman Kevin Comcowich, CEO Matthew Plavan, and Directors Jamie Bechtel, Dr. Albert Bolles, Peter Gajdos, Lilian Shackleford Murray, and Gregory Waller. They oversee the company's strategic direction and operations.

Arcadia Biosciences, Inc. is an agricultural biotechnology company focused on developing traits for crops, with a market capitalization of $6.81 million. As of March 2025, it reported net sales of $1 million and a net profit of $3 million.

As of Jun 18, Arcadia Biosciences, Inc. has a market capitalization of 6.81 million, with net sales of 5.27 million and a net profit of -0.77 million over the latest four quarters. The company reported shareholder's funds of 6.22 million and total assets of 13.52 million as of Dec 24.